
Sosei Group Corporation

# 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference

8 January 2018







### Disclaimer

The material that follows is a presentation of general background information about Sosei Group Corporation and its subsidiaries (collectively, the "Company") as of the date of this presentation. This material has been prepared solely for informational purposes and is not to be construed as a solicitation or an offer to buy or sell any securities and should not be treated as giving investment advice to recipients. It is not targeted to the specific investment objectives, financial situation or particular needs of any recipient. It is not intended to provide the basis for any third party evaluation of any securities or any offering of them and should not be considered as a recommendation that any recipient should subscribe for or purchase any securities.

The information contained herein is in summary form and does not purport to be complete. Certain information has been obtained from public sources. No representation or warranty, either express or implied, by the Company is made as to the accuracy, fairness, or completeness of the information presented herein and no reliance should be placed on the accuracy, fairness, or completeness of such information in the light of new information and/or future events. In addition, the Company may alter, modify or otherwise change in any manner the contents of this presentation, in its own discretion without the obligation to notify any person of such revision or changes.

This presentation contains "forward-looking statements," as that term is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. The words "believe", "expect", "anticipate", "intend", "jplan", "seeks", "estimates", "will" and "may" and similar expressions identify forward looking statements. All statements of historical facts included in this presentation, including, without limitation, those regarding our financial position, business strategy, plans and objectives relating to our products), are forward looking statements. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinevements to differ materially from those in the forward looking statements include, among others, risks associated with product discovery and development, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforesen safety issues resulting from the administration of our products in patients, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our protects, our patients, our relationshow which may render our products obsolete, and other factors. These factors includes in versions with affiliated entities, classed or information to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our protects includes in the flutore. The forward looking statements are based on on merce our products obsolete, and other factors. These factors include, without limitation, those effections of our pa

This presentation does not constitute an offer, or invitation, or solicitation of an offer, to subscribe for or purchase any securities. Neither this presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. Recipients of this presentation are not to construe the contents of this summary as legal, tax or investment advice and recipients should consult their own advisors in this regard.

This presentation and its contents are proprietary confidential information and may not be reproduced, published or otherwise disseminated in whole or in part without the Company's prior written consent. These materials are not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

This presentation contains non-GAAP financial measures. The non-GAAP financial measures contained in this presentation are not measures of financial performance calculated in accordance with IFRS and should not be considered as replacements or alternatives profit, or operating profit, as an indicator of operating performance or as replacements or alternatives to cash flow provided by operating activities or as a measure of liquidity (in each case, as determined in accordance with IFRS). Non-GAAP financial measures should be viewed in addition to, and not as a substitute for, analysis of the Company's results reported in accordance with IFRS.

References to "FY" in this presentation are to the Company's fiscal years, namely the 12-month periods commencing in each case on April 1 of the year indicated and ending on March 31 of the following year, unless specifically otherwise indicated.



## A Japan-listed biotech with a difference

Listed 2004 in Tokyo (TSE Mothers: 4565) Global management team Main scientific campus in the U.K. Market capitalization: c.\$2.0bn

- World-leader in GPCR-focused drug design based on unique IP protected StaR®<sup>1</sup> GPCR technology & enabled SBDD<sup>2</sup> platform
- Partnered clinical-stage pipeline in neurology, immuno-oncology, CNS & other diseases, with up to c.\$6bn in potential economics
- Proprietary pipeline led by dementia with Lewy Bodies (DLB) Phase 2 program in Japan, plus multiple novel candidates in development
- Strategic investment in saRNA therapeutics with lead candidate in Phase 1/2a for liver cancer, an orphan indication
- > Growing royalties from legacy respiratory products provide source non-dilutive cash flows
- Strong cash position of c.\$300m to drive global growth strategy

Tokyo listed, global operations. We are building Japan's first biotech champion



### **Unique management team for a Japan-listed company** Significant pharma and biotech expertise



gsk Syngene

Peter BAINS
Chief Executive Officer
Former Senior VP of International Commercial Development at GSK
Former CEO of Syngene



ACTELION novimmune of Wvectura

Andrew OAKLEY Chief Financial Officer Former CFO of Actelion Pharmaceuticals Ltd Former CFO of Vectura plc



Dr. Malcolm WEIR Chief R&D Officer

CEO and Co-Founder Heptares

Former Head of Molecular Science Division at Glaxo Wellcome



Dr. Tim TASKER Chief Medical Officer

GSK and Former Executive VP of Clinical Development at Evotec



evotec





Dr. Fiona MARSHALL
Chief Scientific Officer
CSO and Co-Founder at Heptares
Former Head of Molecular Pharmacology


Department at Glaxo Wellcome

### Scientific Advisory Board experience






### Three corporate events have shaped Sosei



Our patent-protected StaR® technology enables Structure-Based Drug Design, consolidating our position as the world leader in GPCR medicine discovery and design




## Vast opportunity targeting GPCRs, however many high-value targets remain untapped GPCRs are the backbone of the pharma industry



<sup>1</sup> Source: "Trends in GPCR in Drug Discovery – new agents, targets and indications", Nature Reviews, October 2017 <sup>2</sup> Source: "Unexplored opportunities in the druggable human genome", Nature Reviews, 2016



## StaR® technology enables us to stabilize and "unlock" GPCRs Revolution for GPCR structure-based discovery




- Structural tools of science cannot be applied to native GPCRs
- Results in many sub-optimally drugged targets
- Unstable nature also prevents ability to generate stable antigen to raise antibodies
- Single point mutations stabilize GPCRs to create a StaR® that can be purified and retains function
- StaR® technology is the basis for our integrated structure/ chemistry/ pharmacology platform (SBDD)

StaR<sup>®</sup> proteins enable crystallisation for structural determination, and the technology is protected by a robust IP estate and high levels of know-how.

StaR<sup>®</sup> proteins enable SME, peptide or antibody discovery



## **Risk-balanced strategy to leverage leadership and capitalize on GPCR opportunity** Creates and captures value



Reserving the right to choose which strategy is most appropriate for each drug candidate, with a goal to commercialize ourselves in selected indications and markets



9

**SOSGI** 

Modality

Indication

Product/Program

GPCRs/StaR®

Discoverv

### Advancing a <u>Partnered GPCR pipeline</u> in multiple therapeutic areas Balanced and diversified

Partner

Floauci/Flogram	Modality	Indication	Farmer	Discovery	Freclinical	Phase I	Phase 2	Phase 3	Marker	
M <sub>1</sub> AD agonist	SME	Alzheimer's disease	🤹 Allergan				>			
M <sub>4</sub> AD/Sz agonist	SME	NeuroB Sx in AD	🔅 Allergan							
M <sub>1</sub> /M <sub>4</sub> agonist	SME	AD/NeuroB Sx in AD	🛟 Allergan							
A <sub>2A</sub> antagonist	SME	Cancer I/O	AstraZeneca				>			
CGRP antagonist	SME	Migraine	52370			>				
<b>G G</b>	SME/ mAb	Multiple indications	Pfizer		>					
Č Cr	SME	Pain	Daiichi-Sankyo		>					
<u> </u>	SME	Not disclosed	<b>morphosys</b>		>					
Partnered GPCR Pipeline (Co-development/profit share)										
© <sup>©</sup> ©	PEP	Inflammation	PeptiDream							
G	mAb	Immuno-oncology	kymab							

Multiple big pharma partners, across multiple modalities, validate our StaR® and SBDD approach



Phase 1

Partnered

**GPCR** Pipeline

Proprietary

**GPCR** Pipeline


Phase 2

**Business** 

Model

Preclinical

Market



Phase 3

Strategic


Investment




## **Up to \$6bn in potential economics secured from lead <u>Partnered</u> compounds** Provides potential source of non-dilutive financing

Partner	Program / Indication	Upfront received (US\$m)	Total Development Milestones (US\$m)	Total Sales Milestones (US\$m)	Total UF + Milestones (US\$m)	Milestones Received (US\$m)	Royalty (US\$m)	Additional Details
🔅 Allergan	M <sub>R</sub> PRGM Cognition/Psych.	125	665	2,575	3,365	15	Tiered, double- digit	<ul> <li>Exclusive global rights</li> <li>Allergan committed \$50m to a joint R&amp;D program through Ph 2a</li> </ul>
AstraZeneca	A <sub>2A</sub> Immuno-oncology	10	500		510	22	Tiered, double- digit	<ul> <li>Exclusive global rights to AZD4635</li> <li>Collaboration to discover further A<sub>2A</sub> receptor blocking compounds for development</li> </ul>
ᡪᢧᡜ᠋᠋᠋ᡔᠴ	CGRP Migraine	10	400		410	5	Tiered, double- digit	<ul> <li>Exclusive global rights to novel CGPR antagonists</li> <li>Received research funding</li> </ul>
Pfizer	© C	Nil	~189 per target	N.D.	1,890		Tiered (single digit)	<ul> <li>Discovery of potential novel GPCR agents selected by Pfizer (up to 10 targets)</li> <li>Pfizer will be responsible for developing and commercializing any agents discovered</li> </ul>
TOTAL		145+			6,175	42		

c.\$6bn in potential development, regulatory and commercial milestones to come, in addition to royalties on sales



Selective muscarinic M<sub>1</sub> receptor agonism offers a potential first-in-class therapy for AD patients



activation

5%



Overview of the HTL0018318 muscarinic M<sub>1</sub> agonist

> Xanomeline's development stopped due to unacceptable CV and GI side effects linked to stimulation of  $M_2 \& M_3$ 

De sosei

- HTL0018318 is a potent muscarinic  $M_1$  agonist with negligible  $M_2/M_3$  agonism
- StaR® & SBDD "designed out" unwanted selectivity over the  $M_2 \& M_3$  receptors

```
HTL0018318 is a potential first-in-class therapy for AD
Highly selective M<sub>1</sub> receptor agonist derived from StaR® and SBDD
```

Xanomeline<sup>1</sup>

Cognition V

<u>CV side-effects</u>

<u>GI side-effects</u>

M₁

 $M_2$ 

🐔 Allergan



Phase 1b

HTL0018318

HTI 0018318 is a

selective M<sub>1</sub> receptor

agonist for cognition

M₁

Cognition V

Partnered with:

Partnered with:

AstraZeneca


Phase 1b



Exciting I/O treatment approach

De sosei

### I/O drugs – forecast sales for marketed products (\$bn)<sup>1</sup>



### Potential role of Adenosine A<sub>2A</sub> antagonists in cancer

- Blocks tumor cells' ability to use Adenosine to evade the immune system
- Opportunity in a wide range of tumor types in particular, link to tumors with hypoxia
- Ability to select patients based on biomarkers of elevated adenosine, e.g. CD73
- Potential role both as I/O monotherapy, and in combination with other immunotherapy approaches

Immunotherapies are at the forefront of cancer treatment with strong forecast growth for I/O drugs.  $A_{2A}$  antagonists represent an exciting I/O treatment approach


Source: Management estimates

13 <sup>1</sup> Includes sales forecasts for Keytruda (pembrolizumab), Opdivo (nivolumab), Yervoy (ipilimumab), Tecentriq (atezolizumab), Imfinzi (durvalumab), and Bavencio (avelumab) only



The first  $A_{2A}$  antagonist structurally derived from StaR® and SBDD

### Preclinical summary of AZD4635



### GPCRs/StaR® Business Model Partnered GPCR Pipeline Proprietary GPCR Pipeline Strategic Investment Financials





### Phase 1b trials ongoing

- Ph. 1b trials in patients with solid malignancies (mono/combination therapy) progressing well
- > MTD for monotherapy complete, dose escalation to establish the MTD in combination with IMFINZI<sup>™</sup> near completion
- Progressing with signal seeking Ph. 1b expansion cohorts in a number of tumor types with monotherapy and/or in combination with IMFINZI<sup>TM</sup>

### AZD4635 enhances the anti-tumor activity of anti-PD-L1 checkpoint inhibitors in established MC38 syngenic tumors<sup>1</sup>

### GPCRs/StaR® Business Model Partnered GPCR Pipeline Proprietary GPCR Pipeline Strategic Investment Financials


## <u>Proprietary pipeline</u> now led by M<sub>1</sub> DLB opportunity in Japan

Focus on selected rare/orphan and specialty indications or markets

Product/Program Mode		Indication	Discovery	Preclinical	Phase 1	Phase 2	Phase 3	Market
<b>Proprietary GPCR</b>	Pipeline (	(Go-to-market/commercialize) - fo	rmerly known as	"Wave 2"				
M <sub>1</sub> DLB agonist	SME	Dementia with Lewy Bodies (Japan)						
mGlu₅ NAM	SME	CNS						
MOL 1	SME	Undisclosed						
MOL 2	SME	Undisclosed						
MOL 3	SME	Undisclosed						
MOL 4	SME	Undisclosed						
MOL 5	SME	Undisclosed						

Investment in StaR® technology driving Proprietary GPCR pipeline progress – up to 3 novel drug candidates to enter Phase 1 every year commencing CY2018







## Sosei is advancing HTL0018318 for DLB in Japan

Highly selective M<sub>1</sub> receptor agonist designed by StaR® and SBDD



Phase 2 ready

### Dementia with Lewy Bodies (DLB)

- Progressive neurodegenerative dementia, second most prevalent behind AD (c.1m patients in Japan)
- > Advances in diagnosis have increased DLB awareness
- Social and 'political' priority in Japan to evaluate new treatments
- Potential Muscarinic M<sub>1</sub> agonist for DLB
- Greater cholinergic deficit in DLB than in AD
- Loss of presynaptic cholinergic system reduces effect of donepezil whilst intact post synaptic receptors allows response to M1 agonists

### Overview of our M<sub>1</sub> program for DLB in Japan

- HTL0018318 same compound being advanced by Allergan for AD in our Partnered pipeline
- Phase 2 POC monotherapy study, expected to begin in Japan in 2018
- Strong go-to-market opportunity for Sosei in Japan
  - Leverages our clinical capabilities, and broader track record of successful product development in Japan
  - Satisfies key element of growth strategy manageable indication treated in specialist centres, sizeable market opportunity to build and retain value

Strong go-to-market opportunity for our lead M<sub>1</sub> program in Japan. Significant unmet medical and social need for a new therapeutic approach to tackle DLB in Japan



## Strategic investment in saRNA technology

CEBPA<sup>1</sup> is an attractive, previously 'undruggable' target in liver disease

In May 2017, we acquired a strategic 25.6% stake in MiNA, with an exclusive option to move to 100% ownership at pre-determined economics

### CEBPA regulates multiple pathways in the liver

- Master regulator of liver function
- Increases energy generation, energy utilisation, aminoacid metabolism, glucose uptake
- Inhibitor of oncogenic signaling pathways: mTOR, MAPK and YAP1
- Knock-out mice have impaired liver function
- Knock-in mice have reduced susceptibility to HCC and cirrhosis without observable toxicity

### saRNA is a unique modality for targeting CEBPA

- Extremely low drugability score of 0.01 (c.f. PPARg 3.52) for small molecule therapeutics
- Reversible mode of action eliminates long term risks of gene therapy / CRISPR
- Liposomal formulation minimises non-liver toxicity
- Lead candidate CEBPA currently in a Phase 1/2a clinical trial in patients for liver cancer, an orphan indication

We are excited about the potential of saRNA therapeutics. MiNA's recent deal with Boehringer Ingelheim further supports MiNA/saRNA's potential

 GPCRs/StaR®
 Business
 Partnered
 Proprietary
 Strategic

 Model
 GPCR Pipeline
 GPCR Pipeline
 Investment
 Financials



Phase 1/2a



## SOS61

## Continuing to invest and scale the business

### Allergan upfront milestone in FY2016 drives P&L variance

(JPY m) <sup>1</sup>	FY2015	FY2016	% change (FY15 vs FY16)	H1 FY 2016	H1 FY 2017	% change (H116 vs H117)
Revenue	8,151	18,901 <sup>3</sup>	132%	1 <i>5,</i> 839 <sup>3</sup>	5,314	(66%)
Opex	7,209	6,790	(6%)	3,726	4,299	15%
Cash & cash equivalents	10,068	13,899	na	15,680	12,413	na
Interest-bearing debt	8,837	6,900	na	7,870	10,635	na
						,
(USD m) <sup>2</sup>		FY2016			H1 FY 2017	
Revenue		168.5 <sup>3</sup>			47.4	
Opex		60.5			38.3	
Cash & cash equivalents		123.9			110.6	
Interest-bearing debt		61.5			94.8	

<u>PLUS</u> c.\$200m raised in November 2017 via a Global Offering of shares to international investors. Pro forma cash balance of c.\$300m provides runway of approx. 2-3 years based on organic business plan

<sup>1</sup> reporting currency in JPY

<sup>2</sup>Converted at USD:JPY FX rate 112.9 (JPY:USD FX rate 0.0089) as at 31 March 2017

<sup>3</sup> Includes USD 125m upfront payment from Allergan to Heptares



## Thank you!

Listed 2004 in Tokyo (TSE Mothers: 4565) Global management team Main scientific campus in the U.K. Market capitalization: c.\$2.0bn

- World-leader in GPCR-focused drug design based on unique IP protected StaR®<sup>1</sup> GPCR technology & enabled SBDD<sup>2</sup> platform
- Partnered clinical-stage pipeline in neurology, immuno-oncology, CNS & other diseases, with up to c.\$6bn in potential economics
- Proprietary pipeline led by dementia with Lewy Bodies (DLB) Phase 2 program in Japan, plus multiple novel candidates in development
- Strategic investment in saRNA therapeutics with lead candidate in Phase 1/2a for liver cancer, an orphan indication
- Growing royalties from legacy respiratory products provide source non-dilutive cash flows
- Strong cash position of c.\$300m to drive global growth strategy

Sosei is a Japan-listed biotech with a difference

# Locations

### **SOSEI GROUP**

PMO Hanzomon 11F 2-1 Kojimachi, Chiyoda-ku Tokyo 102-0083 Japan

2nd Floor, London BioScience Innovation Centre 2 Royal College Street London NW1 0NH United Kingdom

www.sosei.com

### **HEPTARES THERAPEUTICS**

BioPark, Broadwater Road Welwyn Garden City Hertfordshire AL7 3AX United Kingdom

Grabenstrasse 11a, CH-8952 Schlieren Zürich, Switzerland

www.heptares.com

